

Contacts

USA



Marion Paolini, PhD, MSc

External Innovation Manager, Servier BioInnovation USA

Tel: +1.857.354.1783

marion.paolini@servier.com



Michele Bernier, MBA

Operations Manager, Servier BioInnovation USA

Tel: +1.857.354.1782

michele.bernier@servier.com

ASIA



Cynthia Wang, MBA, MSc

Director, BD & Licensing, Servier BioInnovation Asia

Tel: + 86 13910100149

cynthia.wang@servier.com




SERVIER BIOINNOVATION

Your One-stop Shop for Innovation and Early-Stage Partnering

- We serve as the 'one-stop shop' for innovators in North America and Asia, sourcing R&D opportunities and expediting BD activities
- Our key stakeholders include world-class academic researchers, technology transfer and development offices, non-profit foundations, patient advocacy organizations, company builders, venture capitalists and strategic biotechnology and pharma partners
- We are responsible for increasing the Servier Group's visibility, attracting talent, and establishing R&D partnerships and managing alliances, through targeted representation in the world's top biomedical innovation centers
- We have been present in the United States (Cambridge, MA) and Asia (Beijing) since 2018

Areas of Interest

Research collaborations to early clinical development: The best modality for right target in the right patient at the right time.

	MEDICAL NEED	BIOLOGY
 ONCOLOGY	Hematological and solid tumors	Apoptosis, immuno-oncology (T-cell focus)
 IMMUNO-INFLAMMATION	Autoimmune disease, including Lupus, Sjögren, systemic sclerosis	Cytokine and immune regulation
 NEUROSCIENCE	Neurodegeneration	Proteinopathies, neuroinflammation

<https://servier.com/en/areas-of-expertise/partnering/>

Partnering with Servier

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

A partner of choice

A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

A partner with a global presence

With €4.7Bn of revenue in 2020 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners

A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets

Our areas of interest



Oncology

Discovery & Early Clinical Focus

Cancer cell Targeting

- Apoptosis (BCL2 family; extrinsic cell death)
- Novel oncogenes, oncogene stability regulators
- Epigenetic regulators (with biomarker validation)
- Synthetic lethality associated with genetic defect

Immuno-oncology

- Stroma/ Tumor micro-environment (e.g., genetically-driven immune contexture)
- T cell activation (e.g. intracellular immune checkpoints)
- Immunosuppression (e.g. Treg targeting)
- Innate immunity (e.g. Type I interferon pathway)

Modalities

- Small molecules (Discovery to Early Clinical stage)
- mAb/bispecifics (Early Clinical stage)

Late stage and commercial opportunities

- We are actively looking at strengthening our portfolio and licensing-in/acquiring commercial and late-stage products (on market ~2023/4)



Immuno-inflammation

Inflammatory & autoimmune disease

- Lupus
- Primary Sjögren syndrome
- Systemic sclerosis
- And other diseases sharing similar pathophysiological mechanisms

Modalities

- small molecules
- mAb/bispecifics



Neuroscience

- Multiple System Atrophy
- Familial Amyotrophic lateral sclerosis
- Hereditary forms of Parkinson's Disease
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy

Modalities

- Small molecules
- ASO
- PROTAC



Cardiovascular & Metabolism diseases

Acquire or license market-ready or mature assets for some geographies